Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48) trial

2016 ◽  
Vol 172 ◽  
pp. 144-151 ◽  
Author(s):  
Alon Eisen ◽  
Robert P. Giugliano ◽  
Christian T. Ruff ◽  
Francesco Nordio ◽  
Harinder S. Gogia ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Factor Xa ◽  
Next Generation ◽  
Nonvalvular Atrial Fibrillation ◽  
The Us

Aspirin and myocardial infarction

1987 ◽  
Vol 25 (5) ◽  
pp. 17-19
Keyword(s):  
Myocardial Infarction ◽  
Drug Administration ◽  
Coronary Thrombosis ◽  
Food And Drug Administration ◽  
Preventive Effect ◽  
Vascular Disorders ◽  
Heart Attacks ◽  
The Us

When we last reviewed the use of aspirin in vascular disorders we concluded that a preventive effect in coronary thrombosis was uncertain.1 In 1985 the US Food and Drug Administration accepted, after reviewing the evidence, that aspirin can reduce the likelihood of heart attacks for some patients.2 How strong is this evidence?

Peritrate is no longer claimed to aid survival

1966 ◽  
Vol 4 (12) ◽  
pp. 47-48
Keyword(s):  
Myocardial Infarction ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Pentaerythritol Tetranitrate ◽  
Sustained Action ◽  
The Us ◽  
Action Preparation

On February 28 the US Food and Drug Administration took the unprecedented step of seizing stocks of Peritrate SA (Warner-Chileott Labs), a sustained-action preparation of pentaerythritol tetranitrate. This was done because the FDA judged advertisements for the drug to be ‘false and misleading’. They implied that the drug increased survival after myocardial infarction by asking ‘Is Peritrate life - sustaining?’, clearly inviting the answer ‘yes’.

scholarly journals Impact of the US Food and Drug Administration–Approved Sex-Specific Cutoff Values for High-Sensitivity Cardiac Troponin T to Diagnose Myocardial Infarction

Circulation ◽  
2018 ◽  
Vol 137 (17) ◽  
pp. 1867-1869 ◽  
Author(s):  
Maria Rubini Gimenez ◽  
Patrick Badertscher ◽  
Raphael Twerenbold ◽  
Jasper Boeddinghaus ◽  
Thomas Nestelberger ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Drug Administration ◽  
Cardiac Troponin ◽  
Troponin T ◽  
Food And Drug Administration ◽  
High Sensitivity ◽  
Cardiac Troponin T ◽  
Cutoff Values ◽  
The Us
Sign in / Sign up

Export Citation Format

Share Document